Table 3.
In vivo efficacy of single doses of JNJ-Q2 and comparators in a murine lower respiratory tract infection model with S. pneumoniae ATCC 6301
| Compound and dosing route (na) | ED50 in mg/kg/dayb (95% fiducial limits) | ED90 in mg/kg/dayc (95% fiducial limits) | P valued |
|---|---|---|---|
| JNJ-Q2 | |||
| p.o. (16) | 7.4 (5.3-10.1) | 19.7 (13.8-38.0) | NA |
| s.c. (16) | 1.9 (0.7-3.3) | 18.3 (9.5-80.3) | NA |
| Moxifloxacin | |||
| p.o. (16) | 14 (8-23) | 41.5 (28.3-84.2) | <0.0086 |
| s.c. (16) | 23 (NL) | NATC | <0.0001 |
| Gemifloxacin | |||
| p.o. (16) | 3.9 (2.2-5.8) | 25.7 (16.4-53.2) | <0.0066 |
| s.c. (16) | 2.0 (1.2-2.9) | 15.2 (8.9-40.6) | <0.0104 |
a
n, number of animals per group.
b
ED50s calculated using SAS version 5. NL, no limits obtained.
c
ED90s calculated using SAS version 9.1. NATC, program not able to calculate.
d
P values represent measurements of the significance of comparisons of dose-response profiles of survival incidence data for JNJ-Q2 and comparators. NA, not applicable.